Non-Hodgkin Lymphoma
Conference Coverage
Drug shows early promise for low-grade lymphoma
follicular lymphoma NEW ORLEANS—The TLR9 agonist SD-101 has produced encouraging early results in patients with low-grade B-cell lymphoma,...
Conference Coverage
Antibody shows activity against ALL, CLL
Photo by Aaron Logan NEW ORLEANS—Preclinical data suggest IMMU-114, a humanized anti-HLA-DR IgG4 antibody, is active against acute and chronic...
News
FDA grants drug accelerated approval for CLL
Photo courtesy of the CDC The US Food and Drug Administration (FDA) has granted accelerated approval for venetoclax (Venclexta) to treat patients...
News
Dual inhibitor shows early promise for DLBCL
The small-molecule inhibitor CUDC-907 can provide disease control in patients with relapsed or refractory lymphoma and multiple myeloma (MM),...
News
MicroRNA could be used to treat DLBCL, team says
A microRNA known as miR-181a dampens signals from the NF-κB pathway and affects the pathogenesis of diffuse large B-cell lymphoma (DLBCL),...
News
Drug ‘not powerful enough’ to treat CTCL
mycosis fungoides Results of a phase 2 trial suggest the drug APO866 is not suitable for the treatment of relapsed or refractory cutaneous T-cell...
News
Lenalidomide prolongs PFS, not OS, in rel/ref MCL
Photo by Esther Dyson Results of the phase 2 SPRINT trial suggest lenalidomide compares favorably to other single-agent therapies for patients...
News
Drug shows early promise for rel/ref NHL
Blinatumomab, a CD19/CD3 bispecific T-cell engager antibody construct, can produce durable responses in patients with relapsed/refractory B-cell...
News
Studies explain how mutations promote lymphoma
New research suggests there are 4 different “locks” that keep the CARD11 protein in check. Researchers say these locks, also known as “repressive...
News
EMA recommends safety measures for idelalisib
Photo courtesy of Gilead Sciences, Inc. In light of recently reported safety concerns, the European Medicines Agency’s (EMA) Pharmacovigilance...
News
Idelalisib trials stopped due to AEs
Photo courtesy of Gilead Sciences The US Food and Drug Administration (FDA) has reported that Gilead Sciences, Inc., is stopping 6 clinical...